Literature DB >> 28384120

Dyslipidemia in subclinical hypothyroidism requires assessment of small dense low density lipoprotein cholesterol (sdLDL-C).

Maida Seferovic Saric1, Miljenka-Jelena Jurasic1, Slavica Sovic1, Bojana Kranjcec1, Tatjana Glivetic1, Vida Demarin1.   

Abstract

BACKGROUND: Usually both hypothyroidism and hyperthyroidism are related to the cardiovascular and cerebrovascular disease development. The relationship between subclinical hypothyroidism has been widely investigated but the findings remain controversial. The aim of the present study was to evaluate the lipid profile in patients with subclinical hypothyroidism (SHypo) in comparison to controls and to determine the association of SHypo and dyslipidemia in attempt to find importance of small dense low-density lipoprotein cholesterol (sdLDL-C) in atherosclerosis.
MATERIAL AND METHODS: In this study we included 100 women, aged 30 to 70 years that were divided into subgroups according to their age. According to the values of levels of thyroid hormones they were divided into euthyroid (control) group (n = 64) and (newly discovered) subclinical hypothyroidism (SHypo) group (n = 36). A high-sensitivity C-reactive protein (hs-CRP) and lipid profile, including small dense low-density lipoprotein cholesterol (sdLDL-C) were determined. Body weight and height were measured and BMI calculated. History of the current illness, medication, alcohol consumption and cigarettes smoking were noted.
RESULTS: Changed lipid profile as well as elevated triglycerides and sdLDL-C were observed in the group with subclinical hypothyroidism compared to the control group.
CONCLUSIONS: It is important to determine serum lipid levels, especially serum sdLDL-C levels at an early stage of subclinical hypothyroidism, since they represent atherogenic LDL particles and are better indicators for dyslipidaemia in subclinical hypothyroidism and the development of atherosclerosis with potential complications such as cardiovascular and cerebrovascular diseases.

Entities:  

Keywords:  cardiovascular risk; cerebrovascular risk; dyslipidemia; small dense low density lipoprotein cholesterol; subclinical hypothyroidism

Mesh:

Substances:

Year:  2017        PMID: 28384120     DOI: 10.1515/rjim-2017-0015

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  5 in total

1.  Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Authors:  Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson
Journal:  Thyroid       Date:  2019-05-13       Impact factor: 6.568

2.  Thyroid and Cardiovascular Disease Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Authors:  Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson
Journal:  Circulation       Date:  2019-05-13       Impact factor: 29.690

3.  The effect of Thyroid Autoimmunity on Dyslipidemia in patients with Euthyroid Hashimoto Thyroiditis.

Authors:  Hasret Cengiz; Taner Demirci; Ceyhun Varim; Ali Tamer
Journal:  Pak J Med Sci       Date:  2021 Sep-Oct       Impact factor: 1.088

Review 4.  Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Arrigo F G Cicero; Andrej Janez; Anca Pantea Stoian; Alper Sonmez; Manfredi Rizzo
Journal:  Medicina (Kaunas)       Date:  2022-02-16       Impact factor: 2.430

5.  gp91phox, a Novel Biomarker Evaluating Oxidative Stress, Is Elevated in Subclinical Hypothyroidism.

Authors:  Xiaochun Ma; Furong Wang; Xiaowen Zhen; Lifang Zhao; Li Fang; Zhenfang Dong; Wenbin Chen; Xiaoming Zhou
Journal:  Int J Endocrinol       Date:  2020-05-06       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.